A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body

NCT02154646 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Neoplasms

Interventions

DRUG: LY2157299
DRUG: Gemcitabine

Sponsor

Eli Lilly and Company